

- COUP-TF.
2. The method of claim 1 wherein the adenovirus packaging repressor is
  3. The method of claim 1 wherein the adenovirus packaging repressor is *lac* repressor.
  4. The method according to claim 1 wherein the propagating step occurs in a first cell line and the packaging repressing step occurs in a second cell line.
  5. The method according to claim 1 wherein the packaging repressing step occurs in a cell line coinfecting with a vector expressing the adenovirus packaging repressor.
  6. An adenovirus vector comprising an adenovirus packaging sequence containing a plurality of COUP-TF binding sites comprising an A repeat VI element.
  7. An adenovirus vector comprising an adenovirus packaging sequence having at least two copies of 5'-TTTGN<sub>8</sub>CG-3' and a plurality of COUP-TF binding sites, comprising an A repeat VI element.
  9. A method of administering adenovirus comprising the steps of:
    - a. encapsidating the adenovirus vector of claim 8, thereby forming an adenovirus;
    - b. isolating said adenovirus;
    - c. preparing said adenovirus in a pharmaceutically acceptable carrier;
    - d. administering said adenovirus to a mammal.
  10. An adenovirus vector containing a packaging signal sequence consisting of at least two copies of 5'-TTTGN<sub>8</sub>CG-3' and an A repeat VI element.

Sub 1314  
2 2  
11. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site is embedded in the packaging signal sequence.

12. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site flanks the packaging signal sequence.

13. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site alternates with the packaging signal sequence.

Sub 1315  
3  
15. An adenovirus vector according to claim 14 wherein an adenovirus packaging repressor binding site is located between packaging signal sequences.

16. An adenovirus vector according to claim 11 or 15 wherein the adenovirus packaging repressor binding site is a *lac* repressor site.

17. An adenovirus vector according to claim 11 or 15 wherein the adenovirus packaging repressor binding site is a E2F binding site.

Sub 1315  
4  
19. A method of administering adenovirus comprising the steps of:  
a. encapsidating the adenovirus vector of claim 10, thereby forming an adenovirus;  
b. isolating said adenovirus  
c. preparing said adenovirus in a pharmaceutically acceptable carrier;  
and  
d. administering said adenovirus to a mammal.